Henry Schein

Henry Schein announced a comprehensive reorganization of its top management, with three senior executives, including Michael S. Ettinger, stepping down from their roles on October 30, 2026. The Executive Management Committee will be replaced by a new Henry Schein Leadership Team and the global supply chain organization will be merged with the sales group. Investors were unsettled and the stock fell about 1.8% in morning trading, as the personnel changes just ahead of the Q2 results on August 4 raised doubts about the execution of ongoing value-creation initiatives and the goal of a $125 million increase in operating income. » More on de.investing.com

Henry Schein is replacing the Executive Management Committee with the new Henry Schein Leadership Team and is integrating the global supply‑chain organization into the global sales group. Michael S. Ettinger, Mark E. Mlotek and James Mullins will leave their current roles on October 30, 2026, and will then serve the company as senior advisors. CEO Fred Lowery says the restructuring is intended to enable faster decision‑making and bring the supply‑chain teams closer to sales customers. » More on de.investing.com

Henry Schein said dental momentum continued into April and May while medical sales were weaker due to a mild respiratory illness season; excluding flu and RSV diagnostics, medical grew mid-single digits. The company reconfirmed its 2026 guidance and reiterated a $125 million net run-rate value creation target by year-end and $200 million over the next several years, with most savings expected to ramp in H2 2026. CEO Fred Lowery is prioritizing AI, commercial alignment and customer value to broaden offerings across dental, medical and technology, and management remains disciplined on M&A while targeting DSOs, specialty products and home solutions. » More on finance.yahoo.com